PER-037-16已完成未知
A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMISED,PARALLEL-GROUP PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OFMASITINIB IN PATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE
AB Science,0 个研究点目标入组 1 人开始时间: 2017年3月22日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 1
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •.1. Male or female patient;2. Age ≥ 50 years, weighing more than ≥ 41kg and with a Body Mass Index (BMI) >18 at screening; 3. Patient and/ or caregiver able to understand the patient card and to follow the patient card procedures in case of signs or symptoms of severe neutropenia or severe cutaneous toxicity, during the first 2 months of treatment; 4. Menopause ≥ 2 years for female patient; 5. Patient with dementia of Alzheimer´s type, according to DSM-IV criteria; 6. Patient with probable Alzheimer´ disease according to NINCDS-ADRDA criteria;7. Patient with MMSE ≥ 12 and ≤ 25 at baseline; 8. Patient treated for a minimum of 6 months with a stable dose of cholinesterase inhibitors (donepezil, rivastigmine or galantamine) at baseline, and/or a stable dose of memantine for a minimum of 6 months at
- •baseline, with no changes foreseen in therapy throughout the study; 9. Patient with adequate organ function at screening and baseline:• Absolute Neutrophils Count (ANC) ≥ 2 x 109/L• Hemoglobin ≥ 10 g/dL• Platelets (PTL) ≥ 100 x 109/L • AST and ALT ≤ 3 ULN• Bilirubin ≤ 1.5 ULN • Albuminemia > 1 x LLN• Creatinine clearance > 50 mL/min • Proteinuria < 30 mg/dL (1+) on the dipstick. If proteinuria ≥ 1+ on the dipstick, 24 hours proteinuria must be < 1.5g/24 hours; 10. Patient with a regular and reliable caregiver. The designated caregiver must be sufficiently familiar with the patient (as determined by the investigator) to provide accurate data. The caregiver must have regular contact with the patient (i.e., an average of 10 or more hours per week), must be able to observe for possible adverse events, must be able to oversee patient’s compliance with the study treatment and to report on the patient’s status and must be able to accompany the patient to all visits; 11. Patient, identified caregiver and, if applicable, patient surrogate able and willing to comply with study visits and procedures per protocol, understand, sign, and date the informed consent form at screening visit prior to any protocol-specific procedures performed; 12. Male patient with a female partner of childbearing potential who agrees to use a highly effective method of
- •contraception and an acceptable method of contraception by his female partner during the study and for 3
- •months after the last treatment intake or who agrees to use an acceptable method of contraception and a highly effective method of contraception by his female partner during the study and for 3 months after the last treatment intake.
排除标准
- •1. Patient with any other cause of dementia not due to Alzheimer´s disease, based on specific examination
- •including a brain neuro-imagery exam within the last 6 months:
- • Other central nervous condition causing progressive deficits in memory and cognition, e.g.
- •cerebrovascular disease (patient with not more than 4 microbleeds and not more than 2 lacunes at the
- •MRI could be enrolled in the study), Parkinson´s disease, Huntington´s disease, brain tumor…
- • Systemic conditions known to cause dementia, e.g., hypothyroidism, untreated vitamin B12 or folic acid
- •deficiency, niacin deficiency, neurosyphilis, HIV infection…
- • Substance-induced dementia
- •2. Patient with Alzheimer disease with severe forms of delusions or delirium (patients with light and mild forms
- •of delusions and delirium will be allowed in the study)
- •3. Patient treated with any registered or putative cognitive/memory enhancer or disease modifier other than
- •donepezil, galantamine, rivastigmine or memantine. (Patient taking Ginkgo Biloba can be enrolled providing
- •it has been taken at a stable dose for at least 6 months).
- •4. Patient with evidence of psychosis and/or use of antipsychotic drugs at screening, or history of significant
- •psychiatric disorder
- •5. Patient with active current bacterial (including tuberculosis), viral (including hepatitis B and C, HIV, EBV,
- •CMV, herpes zoster), fungal, mycobacterium, protozoan, or other infection
- •6. Patient with history of infection requiring hospitalization within 2 weeks of screening
- •7. Patient presenting with cardiac disorders defined by at least one of the following conditions:
- • Patient with recent cardiac history (within 6 months) of:
- •- Acute coronary syndrome
- •- Acute heart failure (class III or IV of the NYHA classification)
- •- Significant ventricular arrhythmia (persistent ventricular tachycardia, ventricular fibrillation,
- •resuscitated sudden death)
- • Patient with cardiac failure class III or IV of the NYHA classification
- • Patient with severe conduction disorders which are not prevented by permanent pacing (atrioventricular block 2 and 3, sino-atrial block)
- • Syncope without known aetiology within 3 months
- • Uncontrolled severe hypertension, according to the judgment of the investigator, or symptomatic
- •hypertension
- •8. Patient with chronic diarrhea
- •9. Patient presenting with oedemas
- •10. Patient with co existing dermatological disease (e.g. eczema, psoriasis) or history of skin allergy
- •11. Patient with history of poor compliance or history of drug/alcohol abuse, or excessive alcohol beverage
- •consumption that would interfere with the ability to comply with the study protocol, or current o r past
- •psychiatric disease that might interfere with the ability to comply with the study protocol or give informed
- •12. Patient with life expectancy < 1 year
- •Previous medications:
- •13. Patient treated with any investigational agent within 4 weeks screening
研究者
相似试验
进行中（未招募）
1 期
A clinical study to determine the efficacy and tolerability of two doses of AllerT for reducing allergy symptoms for patients with Birch allergy.Adult patients, 18-65 years of age, suffering from moderate to severe allergic Rhinitis/Rhinoconjunctivitis to birch pollen during the two preceding birch pollen seasons.MedDRA version: 19.1Level: LLTClassification code 10066093Term: Birch pollen allergySystem Organ Class: 100000004870EUCTR2016-000076-23-SKANERGIS SA450
进行中（未招募）
1 期
A MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL TO ASSESS THE EFFICACY AND TOLERABILITY OF TWO DOSING REGIMENS OF ALLERT, IN ADULTS WITH BIRCH POLLEN ALLERGIC RHINITIS/RHINOCONJUNCTIVITISAdult patients, 18-65 years of age, suffering from moderate to severe allergic Rhinitis/Rhinoconjunctivitis to birch pollen during the two preceding birch pollen seasons.MedDRA version: 19.0Level: LLTClassification code 10066093Term: Birch pollen allergySystem Organ Class: 100000004870EUCTR2016-000076-23-FIANERGIS SA450
进行中（未招募）
1 期
A clinical study to determine the efficacy and tolerability of two doses of AllerT for reducing allergy symptoms for patients with Birch allergy.Adult patients, 18-65 years of age, suffering from moderate to severe allergic Rhinitis/Rhinoconjunctivitis to birch pollen during the two preceding birch pollen seasons.MedDRA version: 19.0Level: LLTClassification code 10066093Term: Birch pollen allergySystem Organ Class: 100000004870EUCTR2016-000076-23-LTANERGIS SA450
进行中（未招募）
1 期
A clinical study to determine the efficacy and tolerability of two doses of AllerT for reducing allergy symptoms for patients with Birch allergy.Adult patients, 18-65 years of age, suffering from moderate to severe allergic Rhinitis/Rhinoconjunctivitis to birch pollen during the two preceding birch pollen seasons.MedDRA version: 20.0Level: LLTClassification code 10066093Term: Birch pollen allergySystem Organ Class: 100000023864EUCTR2016-000076-23-DEANERGIS SA450
进行中（未招募）
1 期
A MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED, ASCENDING DOSE, CLINICAL TRIAL OF INTRA-VENOUS MICROPLASMIN ADMINISTRATION IN PATIENTS WITH ACUTE ISCHEMIC STROKE - MITI-IVEUCTR2005-001074-27-GBThromboGenics Ltd.40